Online inquiry

IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7862MR)

This product GTTS-WQ7862MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APCS gene. The antibody can be applied in AL amyloidosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001639.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 325
UniProt ID P02743
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7862MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11730MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ4170MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ9591MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ7810MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ7384MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ9638MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ15378MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ13069MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW